Finance & Capital Markets

  1. Biotech Angel Investing With Yaniv Sneor 5/21/2025

    On this week's Business of Biotech episode, Yaniv Sneor, founder of the Mid Atlantic Bio Angels and CEO at Native State Therapeutics, explains how life science angel investors evaluate biotech startups, and offers tips for young drug developers in search of funding. The conversation covers how to create a successful pitch, red flags for potential investors, the importance of angel investing syndicates, the sweet spots for exit timelines and funding amounts, and why it still makes sense to invest in biotech over other industry sectors.

  2. Fed Funding: Creative Capital Generation With James Thomas Coates, Ph.D. 8/1/2022

    As biotech capital markets continue to restrict access to funding for emerging biopharmas, you might be surprised by how many federal dollars get left on the negotiating table. To that end, James Thomas Coates, Ph.D. and his team at Decisive Point have carved out a niche in the venture capital space.

  3. Building On Pandemic Progress With Barinthus Biotherapeutics' Bill Enright 10/27/2024

    It sure seems like Bill Enright has a knack for making big moves at inopportune times, then turning the expected outcome on its ear. For example, he signed on as CEO at Altimmune when the company was struggling mightily. Enright had a turnaround plan in hand, but as he was in the thick of a non-deal road show to execute said plan, Lehmen Brothers collapsed. On this episode of the Business of Biotech, we'll learn how he flipped the script and other harrowing tales from the trenches. 

  4. Public Sector Forged, Private Sector Tested With Renovaro BioSciences' Mark Dybul, M.D. 12/6/2023

    During his leadership of the President's Emergency Plan for AIDS Relief during the George W. Bush administration, Dr. Mark Dybul, M.D. shepherded programs credited with saving more than 25 million lives. For many years after that public service drew to a close, he continued the mission as executive director of The Global Fund to Fight AIDS, Tuberculosis, and Malaria--working in lockstep with not only the world's leading scientists, but the likes of Bono and Sir Elton John along the way. 

  5. Serving The Underserved With Gates MRI's Claire Wagner, M.D. 11/10/2024

    On this episode of the Business of Biotech, Bill and Melinda Gates Medical Research Institute's Dr. Claire Wagner joins us to share insights into her work as head of Corporate Strategy and Market Access there.

  6. Funding A Neurodegeneration Startup With Coya Therapeutics' Howard Berman 5/10/2023

    Like many of us, Howard Berman, Ph.D. has personal experience with the tragedy of cognitive decline. Neurodegenerative disorders are on the rise, and when one afflicted his father — a triple board-certified physician — he saw firsthand that they don't discriminate. Berman has dedicated his career to addressing neuro, autoimmune, and metabolic diseases, having founded Nicoya Health in 2020 and overseeing its merger with Coya Therapeutics the following year. The company came out of the gates this year fueled by an 11th-hour 2022 IPO, one of just a dozen on the year. Berman joined the Business of Biotech to share his strategy during a stingy stretch in biotech capital markets. 

  7. The Innovator's Dilemma with Lumen Bioscience's Brian Finrow, J.D. 3/4/2024

    In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity breeds skepticism from the investment community. Brian Finrow, J.D. embraces that reality and the challenges that come with it.

  8. Episode 2: The Business Of Biotech: Allan Shaw 8/13/2020

    There are few better suited to advise the leaders of new and emerging biopharma companies on the building blocks of a biotech startup than Allan Shaw. That's why we chose Shaw to help us kick off our Business of Biotech podcast series with an overview of the episodes to come. In addition to his work on the financial front lines of several biotechs, Shaw holds multiple board of director roles with startup biopharma firms, and he advises dozens more in his role as special adviser. On this episode, we'll preview the series and absorb Shaw's to-the-point, practical advice on winning finances, building a pitch, assembling a biotech all-star team, leaving the incubator, navigating early regulatory considerations, and a whole lot more. The Business Of Biotech is produced by BioProcess Online and brought to you with the support of Cytiva.

  9. Mission-Driven Dementia Funding with DDF's Jonathan Behr 6/9/2024

    If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He built a distinguished venture capital career on the back of an MIT Ph.D. in biological engineering, having co-founded no fewer than 7 life sciences companies, served on or observed the boards of at least 17, and led investments at Pure Tech Ventures, the JDRF T1D Fund, SV Health investors, and now, the Dementia Discovery Fund, where he's a partner.

  10. Building A Biotech Hub With Intellia Therapeutics' John Leonard, M.D. 1/13/2024

    We spend a lot of time talking with our guests about building biotech companies. That’s true of this episode too, but today we’re taking a step further with John Leonard, M.D., longtime CEO at Intellia Therapeutics.